ATP1B2

Summary

ATP1B2 (ATPase Na+/K+ transporting subunit beta 2, HGNC:805) is a protein-coding gene on chromosome 17p13.1, encoding Sodium/potassium-transporting ATPase subunit beta-2 (P14415). This is the non-catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of Na(+) and K(+) ions across the plasma membrane.

The protein encoded by this gene belongs to the family of Na+/K+ and H+/K+ ATPases beta chain proteins, and to the subfamily of Na+/K+ -ATPases. Na+/K+ -ATPase is an integral membrane protein responsible for establishing and maintaining the electrochemical gradients of Na and K ions across the plasma membrane. These gradients are essential for osmoregulation, for sodium-coupled transport of a variety of organic and inorganic molecules, and for electrical excitability of nerve and muscle. This enzyme is composed of two subunits, a large catalytic subunit (alpha) and a smaller glycoprotein subunit (beta). The beta subunit regulates, through assembly of alpha/beta heterodimers, the number of sodium pumps transported to the plasma membrane. The glycoprotein subunit of Na+/K+ -ATPase is encoded by multiple genes. This gene encodes a beta 2 subunit. Two transcript variants encoding different isoforms have been found for this gene.

Source: NCBI Gene 482 — RefSeq curated summary.

At a glance

• GWAS associations: 18
• Clinical variants (ClinVar): 49 total
• Druggable target: yes — 5 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_001678

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:805
Approved symbol	ATP1B2
Name	ATPase Na+/K+ transporting subunit beta 2
Location	17p13.1
Locus type	gene with protein product
Status	Approved
Aliases	AMOG
Ensembl gene	ENSG00000129244
Ensembl biotype	protein_coding
OMIM	182331
Entrez	482

Gene structure

Transcript identifiers

Ensembl transcripts: 6 — 6 protein_coding

ENST00000250111, ENST00000577026, ENST00000577113, ENST00000896722, ENST00000937621, ENST00000937622

RefSeq mRNA: 2 — MANE Select: NM_001678 NM_001303263, NM_001678

CCDS: CCDS32550

Canonical transcript exons

ENST00000250111 — 7 exons

Exon	Start	End
ENSE00000887389	7653374	7653502
ENSE00000887391	7654052	7654257
ENSE00000887392	7654628	7654684
ENSE00000887393	7655527	7655625
ENSE00001147379	7655731	7657770
ENSE00001147384	7650926	7651630
ENSE00003608270	7653841	7653945

Expression profiles

Bgee: expression breadth ubiquitous, 221 present calls, max score 99.12.

FANTOM5 (CAGE): breadth broad, TPM avg 72.8918 / max 5778.8011, expressed in 674 samples.

FANTOM5 promoters (11 alternative TSS)

Promoter ID	TPM avg	Samples expressed
159284	70.5111	669
159290	0.9638	195
159293	0.5920	121
159292	0.2110	72
159291	0.1530	67
159288	0.1079	62
159289	0.0901	54
159311	0.0864	30
159309	0.0821	45
159312	0.0544	14

Top tissues by expression

296 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right hemisphere of cerebellum	UBERON:0014890	99.12	gold quality
cerebellar hemisphere	UBERON:0002245	98.96	gold quality
cerebellar cortex	UBERON:0002129	98.89	gold quality
right frontal lobe	UBERON:0002810	98.35	gold quality
caudate nucleus	UBERON:0001873	98.28	gold quality
nucleus accumbens	UBERON:0001882	98.24	gold quality
paraflocculus	UBERON:0005351	98.23	gold quality
cerebellum	UBERON:0002037	98.18	gold quality
amygdala	UBERON:0001876	97.91	gold quality
putamen	UBERON:0001874	97.88	gold quality
dorsal motor nucleus of vagus nerve	UBERON:0002870	97.79	gold quality
ventricular zone	UBERON:0003053	97.65	gold quality
middle frontal gyrus	UBERON:0002702	97.26	gold quality
inferior olivary complex	UBERON:0002127	97.25	gold quality
entorhinal cortex	UBERON:0002728	97.01	gold quality
cingulate cortex	UBERON:0003027	97.01	gold quality
anterior cingulate cortex	UBERON:0009835	96.97	gold quality
temporal lobe	UBERON:0001871	96.93	gold quality
medial globus pallidus	UBERON:0002477	96.86	gold quality
hypothalamus	UBERON:0001898	96.58	gold quality
Brodmann (1909) area 9	UBERON:0013540	96.53	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	96.34	gold quality
lateral globus pallidus	UBERON:0002476	96.25	gold quality
postcentral gyrus	UBERON:0002581	96.24	gold quality
telencephalon	UBERON:0001893	96.13	gold quality
globus pallidus	UBERON:0001875	95.97	gold quality
Ammon’s horn	UBERON:0001954	95.95	gold quality
neocortex	UBERON:0001950	95.76	gold quality
frontal cortex	UBERON:0001870	95.72	gold quality
brain	UBERON:0000955	95.70	gold quality

Single-cell (SCXA)

Detected in 5 experiment(s), a significant marker in 5.

Experiment	Marker?	Max mean expression
E-GEOD-84465	yes	599.31
E-GEOD-93593	yes	288.41
E-GEOD-135922	yes	13.61
E-HCAD-25	yes	4.23
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

138 targeting ATP1B2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-4747-5P	100.00	67.90	2681
HSA-MIR-5196-5P	100.00	67.98	2761
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-6758-5P	100.00	66.21	1470
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-6856-5P	100.00	65.47	1298
HSA-MIR-4510	100.00	66.60	2050
HSA-MIR-6127	100.00	66.76	2188
HSA-MIR-6129	100.00	66.46	2080
HSA-MIR-6130	100.00	66.69	2012
HSA-MIR-6133	100.00	66.48	2064
HSA-MIR-6748-5P	100.00	65.81	1057
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-12118	100.00	65.88	1270
HSA-MIR-4476	100.00	68.18	2030
HSA-MIR-6876-5P	100.00	67.68	2126
HSA-MIR-4514	99.99	67.10	1870
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-4534	99.99	66.58	1907
HSA-MIR-3173-3P	99.98	66.49	1217
HSA-MIR-6891-5P	99.98	66.53	1372
HSA-MIR-103A-3P	99.98	69.14	1595
HSA-MIR-107	99.98	69.14	1595
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-548AN	99.97	70.91	2817

Literature-anchored findings (GeneRIF, showing 11)

• Results demonstrated that the sodium-potassium ATPase beta2 subunit (NKA1b2) was localized both in the neuronal cytoplasm and cellular membrane. (PMID:15294280)
• We identified interesting novel candidate genes that likely contribute to glioma progression and provide first evidence for a role of epigenetic silencing of AMOG in malignant glioma cells. (PMID:16865689)
• Common genetic variation in TP53 and its flanking genes (ATP1B2) found no significant overall associations between SNPs in TP53 and breast cancer risk (PMID:17683073)
• The strong expression of AMOG within the precursor cells of gangliogliomas may represent an additional marker for the diagnostic evaluation of these glioneuronal lesions (PMID:19371356)
• the ER quality control system allows export only of assembled alpha-beta complexes to the Golgi, whereas the number of alpha(1) subunits in the ER determines the amount of the alpha-beta complexes (PMID:19764716)
• The AMOG expression pattern with altered cellular distribution observed in malformations of cortical development suggests that AMOG might contribute to abnormal cortical development via mTOR activation. (PMID:20656459)
• analysis of pathways for maturation of the Na,K-ATPase beta1 and beta2 subunits in the endoplasmic reticulum (PMID:20937802)
• Retinoschisin, the protein involved in the pathogenesis of X-linked juvenile retinoschisis, membrane association is severely impaired in the absence of ATP1A3 and ATP1B2. (PMID:21196491)
• different members of the Na,K-ATPase beta subunit family may have specialized functions. (PMID:2538450)
• AMOG and L1 interdependently regulate their expression levels not only in U-87 MG cells but also in U251 and SHG44 human glioma cell lines. The capacity of AMOG to reduce L1 expression suggests that methods for increasing AMOG expression may provide a therapeutic choice for the management of glial tumors with high expression of L1. (PMID:31510944)
• The beta2-Subunit (AMOG) of Human Na(+), K(+)-ATPase Is a Homophilic Adhesion Molecule. (PMID:35887102)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	atp1b2b	ENSDARG00000034424
danio_rerio	atp1b2a	ENSDARG00000099203
mus_musculus	Atp1b2	ENSMUSG00000041329
rattus_norvegicus	Atp1b2	ENSRNOG00000011227

Paralogs (4): ATP1B3 (ENSG00000069849), ATP1B4 (ENSG00000101892), ATP1B1 (ENSG00000143153), ATP4B (ENSG00000186009)

Protein

Protein identifiers

Sodium/potassium-transporting ATPase subunit beta-2 — P14415 (reviewed: P14415)

Alternative names: Adhesion molecule in glia, Sodium/potassium-dependent ATPase subunit beta-2

All UniProt accessions (3): P14415, I3L1V9, I3L3J8

UniProt curated annotations — full annotation on UniProt →

Function. This is the non-catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of Na(+) and K(+) ions across the plasma membrane. The exact function of the beta-2 subunit is not known. Mediates cell adhesion of neurons and astrocytes, and promotes neurite outgrowth.

Subunit / interactions. The sodium/potassium-transporting ATPase is composed of a catalytic alpha subunit, an auxiliary non-catalytic beta subunit and an additional regulatory subunit. Interacts with isoform 2 of BSG.

Subcellular location. Cell membrane.

Domain organisation. The C-terminal lobe folds into an immunoglobulin-like domain and mediates cell adhesion properties.

Similarity. Belongs to the X(+)/potassium ATPases subunit beta family.

RefSeq proteins (2): NP_001290192, NP_001669* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000402	Na/K_ATPase_sub_beta	Family
IPR038702	Na/K_ATPase_sub_beta_sf	Homologous_superfamily

Pfam: PF00287

UniProt features (21 total): glycosylation site 7, sequence conflict 4, disulfide bond 3, topological domain 2, sequence variant 2, chain 1, transmembrane region 1, region of interest 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P14415-F1	90.04	0.66

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (3): 129–150, 160–177, 200–261

Glycosylation sites (7): 197, 238, 96, 118, 153, 159, 193

Function

Pathways and Gene Ontology

Reactome pathways

14 pathways

ID	Pathway
R-HSA-210991	Basigin interactions
R-HSA-5578775	Ion homeostasis
R-HSA-936837	Ion transport by P-type ATPases
R-HSA-9679191	Potential therapeutics for SARS
R-HSA-109582	Hemostasis
R-HSA-1643685	Disease
R-HSA-202733	Cell surface interactions at the vascular wall
R-HSA-382551	Transport of small molecules
R-HSA-397014	Muscle contraction
R-HSA-5576891	Cardiac conduction
R-HSA-5663205	Infectious disease
R-HSA-9679506	SARS-CoV Infections
R-HSA-9824446	Viral Infection Pathways
R-HSA-983712	Ion channel transport

MSigDB gene sets: 307 (showing top): GOBP_POTASSIUM_ION_TRANSPORT, GOBP_HINDBRAIN_DEVELOPMENT, RRAGTTGT_UNKNOWN, GOBP_BEHAVIOR, GOBP_CIRCULATORY_SYSTEM_PROCESS, GGGNRMNNYCAT_UNKNOWN, RORA1_01, GOBP_SODIUM_ION_TRANSMEMBRANE_TRANSPORT, MODULE_45, GOCC_CELL_SURFACE, GOBP_POTASSIUM_ION_HOMEOSTASIS, GOBP_NEUROGENESIS, MEF2_02, GOBP_POSITIVE_REGULATION_OF_SODIUM_ION_TRANSPORT, MODULE_16

GO Biological Process (24): retina homeostasis (GO:0001895), intracellular sodium ion homeostasis (GO:0006883), positive regulation of neuron projection development (GO:0010976), lateral ventricle development (GO:0021670), third ventricle development (GO:0021678), neuronal-glial interaction involved in hindbrain glial-mediated radial cell migration (GO:0021944), intracellular potassium ion homeostasis (GO:0030007), cell-substrate adhesion (GO:0031589), sodium ion export across plasma membrane (GO:0036376), photoreceptor cell maintenance (GO:0045494), protein stabilization (GO:0050821), motor behavior (GO:0061744), membrane repolarization (GO:0086009), cell communication by electrical coupling involved in cardiac conduction (GO:0086064), plasma membrane bounded cell projection organization (GO:0120036), transport across blood-brain barrier (GO:0150104), positive regulation of sodium ion export across plasma membrane (GO:1903278), positive regulation of potassium ion import across plasma membrane (GO:1903288), negative regulation of glial cell migration (GO:1903976), potassium ion import across plasma membrane (GO:1990573), monoatomic ion transport (GO:0006811), potassium ion transport (GO:0006813), sodium ion transport (GO:0006814), cell adhesion (GO:0007155)

GO Molecular Function (6): ATPase activator activity (GO:0001671), protein-macromolecule adaptor activity (GO:0030674), protein heterodimerization activity (GO:0046982), ATPase binding (GO:0051117), transporter activator activity (GO:0141109), protein binding (GO:0005515)

GO Cellular Component (14): photoreceptor inner segment (GO:0001917), cytoplasm (GO:0005737), plasma membrane (GO:0005886), sodium:potassium-exchanging ATPase complex (GO:0005890), external side of plasma membrane (GO:0009897), membrane (GO:0016020), apical plasma membrane (GO:0016324), lateral plasma membrane (GO:0016328), cell projection membrane (GO:0031253), cell body membrane (GO:0044298), cell periphery (GO:0071944), astrocyte projection (GO:0097449), astrocyte end-foot (GO:0097450), neuron to neuron synapse (GO:0098984)

Reactome top-level categories

Rollup of top-10 pathways:

Category	Pathways
Cell surface interactions at the vascular wall	1
Cardiac conduction	1
Ion channel transport	1
SARS-CoV Infections	1
Hemostasis	1
Muscle contraction	1
Disease	1
Viral Infection Pathways	1
Infectious disease	1
Transport of small molecules	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	6
plasma membrane	3
intracellular monoatomic cation homeostasis	2
ventricular system development	2
anatomical structure development	2
molecular function activator activity	2
plasma membrane region	2
tissue homeostasis	1
sodium ion homeostasis	1
regulation of neuron projection development	1
neuron projection development	1
positive regulation of cell projection organization	1
telencephalon development	1
hindbrain radial glia guided cell migration	1
cell-cell adhesion	1
potassium ion homeostasis	1
cell adhesion	1
sodium ion transmembrane transport	1
export across plasma membrane	1
retina homeostasis	1
multicellular organismal process	1
regulation of protein stability	1
behavior	1
regulation of membrane potential	1
cell communication by electrical coupling	1
cardiac conduction	1
cell communication involved in cardiac conduction	1
cell projection organization	1
vascular transport	1
sodium ion export across plasma membrane	1
positive regulation of sodium ion transmembrane transport	1
regulation of sodium ion export across plasma membrane	1
positive regulation of potassium ion transmembrane transport	1
regulation of potassium ion import	1
potassium ion import across plasma membrane	1
glial cell migration	1
negative regulation of cell migration	1
regulation of glial cell migration	1
potassium ion transmembrane transport	1
inorganic cation import across plasma membrane	1

Protein interactions and networks

STRING

1508 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ATP1B2	ATP1A2	P50993	888
ATP1B2	ATP1A3	P13637	801
ATP1B2	ZNF3	P13683	769
ATP1B2	ATP1A4	Q13733	769
ATP1B2	ASGR2	P07307	765
ATP1B2	ATP1A1	P05023	763
ATP1B2	ASGR1	P07306	749
ATP1B2	PIGQ	Q9BRB3	710
ATP1B2	ATP1B1	P05026	690
ATP1B2	ST3GAL4	Q11206	497
ATP1B2	ATP2B1	P20020	492
ATP1B2	ATP1B3	P54709	419
ATP1B2	KCNJ10	P78508	404
ATP1B2	NNAT	Q16517	385
ATP1B2	CD59	P13987	383

IntAct

11 interactions, top by confidence:

A	B	Type	Score
ATP1B2	RTN4	psi-mi:“MI:0915”(physical association)	0.400
RS1	ATP1A3	psi-mi:“MI:0914”(association)	0.350
APBB1	SSPOP	psi-mi:“MI:0914”(association)	0.350
MAPT	SHTN1	psi-mi:“MI:0914”(association)	0.350
CANX	HLA-A	psi-mi:“MI:0914”(association)	0.350
ATP1A3	TMEM223	psi-mi:“MI:0914”(association)	0.350
TSPAN31	TMEM120B	psi-mi:“MI:0914”(association)	0.350
ATP1B2	CLGN	psi-mi:“MI:0914”(association)	0.350

BioGRID (21): COPG2 (Affinity Capture-MS), ATP1A1 (Co-fractionation), ATP5F1 (Co-fractionation), RPL26 (Co-fractionation), RPLP2 (Co-fractionation), RPS18 (Co-fractionation), RPS8 (Co-fractionation), RTN4 (Affinity Capture-MS), ATP1B2 (Affinity Capture-MS), ATP1B2 (Two-hybrid), GNMT (Affinity Capture-MS), ATP1B2 (Affinity Capture-MS), RTN4 (Affinity Capture-MS), ATP1B2 (Affinity Capture-MS), CLGN (Affinity Capture-MS)

ESM2 similar proteins: A5A6J8, P05026, P05027, P05028, P05029, P06583, P07340, P08251, P13638, P14094, P14231, P14415, P18434, P18597, P18598, P21188, P30715, P30716, P33704, P33879, P43002, P50992, P51164, P51165, P51575, P51577, P54709, Q17QL5, Q202B1, Q24048, Q28030, Q2HZ96, Q4R4V5, Q5E9U1, Q5F362, Q5J583, Q5R6C0, Q5R8S8, Q6AY41, Q8L8W0

Diamond homologs: A5A6J8, A7MB71, P05026, P05027, P05028, P05029, P06583, P07340, P08251, P13638, P14094, P14231, P14415, P18434, P18597, P18598, P21188, P25169, P30715, P30716, P33704, P33879, P43002, P51165, P54709, P97370, Q202B1, Q24046, Q28030, Q2HZ96, Q3T0C6, Q4R4V5, Q5J583, Q5R8S8, Q60489, Q63377, Q8WMG3, Q99ME6, Q9BDK6, Q9GLC3

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

49 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	43
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1274 predictions. Top by Δscore:

Variant	Effect	Δscore
17:7651593:G:GT	donor_gain	1.0000
17:7651628:GGG:G	donor_gain	1.0000
17:7651629:GG:G	donor_gain	1.0000
17:7651629:GGG:G	donor_gain	1.0000
17:7651630:GG:G	donor_gain	1.0000
17:7653372:A:AG	acceptor_gain	1.0000
17:7653373:G:GG	acceptor_gain	1.0000
17:7653373:GC:G	acceptor_gain	1.0000
17:7653373:GCCT:G	acceptor_gain	1.0000
17:7653373:GCCTT:G	acceptor_gain	1.0000
17:7653404:AT:A	acceptor_gain	1.0000
17:7653404:ATG:A	acceptor_gain	1.0000
17:7653405:T:G	acceptor_gain	1.0000
17:7653405:T:TA	acceptor_gain	1.0000
17:7653406:G:A	acceptor_gain	1.0000
17:7653501:GG:G	donor_gain	1.0000
17:7653501:GGGT:G	donor_loss	1.0000
17:7653502:GG:G	donor_gain	1.0000
17:7653502:GGTG:G	donor_loss	1.0000
17:7653503:G:C	donor_loss	1.0000
17:7653503:G:GG	donor_gain	1.0000
17:7653504:T:A	donor_loss	1.0000
17:7653832:T:A	acceptor_gain	1.0000
17:7653838:TAGGC:T	acceptor_loss	1.0000
17:7653839:A:AG	acceptor_gain	1.0000
17:7653840:G:GG	acceptor_gain	1.0000
17:7653840:G:GT	acceptor_loss	1.0000
17:7653840:GGCTT:G	acceptor_gain	1.0000
17:7653941:GGAGC:G	donor_gain	1.0000
17:7653942:GAGC:G	donor_gain	1.0000

AlphaMissense

1954 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:7654153:T:A	C150S	1.000
17:7654154:G:C	C150S	1.000
17:7654673:T:A	C200S	1.000
17:7654674:G:C	C200S	1.000
17:7655803:T:A	C261S	1.000
17:7655803:T:C	C261R	1.000
17:7655804:G:C	C261S	1.000
17:7655851:T:C	F277L	1.000
17:7655853:C:A	F277L	1.000
17:7655853:C:G	F277L	1.000
17:7651612:C:A	R32S	0.999
17:7653424:T:C	F55L	0.999
17:7653426:C:A	F55L	0.999
17:7653426:C:G	F55L	0.999
17:7653473:C:A	P71H	0.999
17:7654090:T:A	C129S	0.999
17:7654090:T:C	C129R	0.999
17:7654091:G:A	C129Y	0.999
17:7654091:G:C	C129S	0.999
17:7654092:C:G	C129W	0.999
17:7654153:T:C	C150R	0.999
17:7654154:G:A	C150Y	0.999
17:7654154:G:T	C150F	0.999
17:7654155:C:G	C150W	0.999
17:7654159:T:C	F152L	0.999
17:7654160:T:C	F152S	0.999
17:7654160:T:G	F152C	0.999
17:7654161:C:A	F152L	0.999
17:7654161:C:G	F152L	0.999
17:7654183:T:A	C160S	0.999

dbSNP variants (sampled 300 via entrez): RS1000141906 (17:7656112 A>G), RS1000745886 (17:7654971 G>A), RS1000851438 (17:7649934 T>C), RS1000861094 (17:7649405 T>A,C), RS1000873891 (17:7645101 C>T), RS1001012398 (17:7655724 G>A,C,T), RS1001528461 (17:7655992 G>T), RS1001627161 (17:7652750 T>G), RS1001700981 (17:7653638 T>C), RS1001759346 (17:7646161 A>G,T), RS1001968964 (17:7651400 C>T), RS1002131423 (17:7657403 C>T), RS1002418755 (17:7657153 A>C), RS1002930865 (17:7654058 A>G,T), RS1003169580 (17:7646432 A>G,T)

Disease associations

OMIM: gene MIM:182331 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

18 associations (top):

Study	Trait	p-value
GCST001554_1	Sex hormone-binding globulin levels	2.000000e-16
GCST002568_2	Esophageal squamous cell carcinoma	3.000000e-13
GCST006190_4	Diastolic blood pressure x smoking status (ever vs never) interaction (2df test)	3.000000e-10
GCST006190_54	Diastolic blood pressure x smoking status (ever vs never) interaction (2df test)	3.000000e-08
GCST006192_52	Systolic blood pressure x smoking status (ever vs never) interaction (2df test)	8.000000e-11
GCST006192_75	Systolic blood pressure x smoking status (ever vs never) interaction (2df test)	2.000000e-12
GCST006193_37	Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test)	9.000000e-11
GCST006193_75	Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test)	9.000000e-09
GCST006195_19	Systolic blood pressure x smoking status (current vs non-current) interaction (2df test)	3.000000e-11
GCST006195_69	Systolic blood pressure x smoking status (current vs non-current) interaction (2df test)	1.000000e-12
GCST009380_7	Type 2 diabetes (adjusted for BMI)	1.000000e-10
GCST009380_8	Type 2 diabetes (adjusted for BMI)	5.000000e-06
GCST010002_119	Refractive error	3.000000e-22
GCST010703_158	Brain morphology (MOSTest)	3.000000e-09
GCST90002402_436	Platelet count	2.000000e-13
GCST90002404_349	Red cell distribution width	1.000000e-17
GCST90020029_827	Waist circumference adjusted for body mass index	6.000000e-12
GCST90020029_828	Waist circumference adjusted for body mass index	5.000000e-10

EFO canonical traits (8, from GWAS)

EFO ID	Trait name
EFO:0004696	sex hormone-binding globulin measurement
EFO:0006336	diastolic blood pressure
EFO:0006527	smoking status measurement
EFO:0006335	systolic blood pressure
EFO:0004346	neuroimaging measurement
EFO:0004309	platelet count
EFO:0009188	Red cell distribution width
EFO:0007789	BMI-adjusted waist circumference

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (2): CHEMBL2095186 (PROTEIN COMPLEX GROUP), CHEMBL6066561 (PROTEIN COMPLEX)

Molecules with ChEMBL bioactivity

5 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 160,774 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1503	OMEPRAZOLE	4	52,284
CHEMBL1751	DIGOXIN	4	67,342
CHEMBL254219	DIGITOXIN	4	16,757
CHEMBL480	LANSOPRAZOLE	4	24,317
CHEMBL2068971	ROSTAFUROXIN	2	74

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: transporter — Na⁺/K⁺-ATPases

ChEMBL bioactivities

235 potent at pChembl≥5 of 287 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.52	IC50	3	nM	CHEMBL2092909
8.32	IC50	4.79	nM	CHEMBL1651648
8.29	Ki	5.1	nM	CHEMBL5876237
8.28	Ki	5.3	nM	CHEMBL5879229
8.27	Ki	5.4	nM	CHEMBL5765464
8.22	Ki	6	nM	CHEMBL5879229
8.17	Ki	6.8	nM	CHEMBL5832044
8.17	IC50	6.79	nM	CHEMBL1651648
8.15	IC50	7	nM	CHEMBL2092738
8.15	IC50	7.04	nM	CHEMBL1651624
8.10	IC50	8	nM	CHEMBL3085467
8.10	IC50	8	nM	CHEMBL3085497
8.10	Ki	8	nM	CHEMBL5765464
8.10	IC50	8	nM	DIGITOXIGENIN
8.10	IC50	8	nM	DIGITOXIN
8.05	IC50	9	nM	CHEMBL3085468
8.00	Ki	10	nM	CHEMBL5748673
7.98	Ki	10.5	nM	CHEMBL5957388
7.98	IC50	10.5	nM	CHEMBL3349024
7.97	IC50	10.7	nM	CHEMBL3350144
7.92	Ki	12.1	nM	CHEMBL6026321
7.92	IC50	12	nM	CHEMBL2069010
7.89	Ki	13	nM	CHEMBL6056661
7.84	Ki	14.3	nM	CHEMBL5851200
7.82	Ki	15.3	nM	CHEMBL5910596
7.80	IC50	16	nM	CHEMBL2068887
7.80	IC50	16	nM	CHEMBL3349024
7.79	Ki	16.4	nM	CHEMBL6031986
7.78	Ki	16.7	nM	CHEMBL5791351
7.75	IC50	17.8	nM	CHEMBL1159613
7.74	Ki	18.1	nM	CHEMBL6030183
7.74	Ki	18.4	nM	CHEMBL5780414
7.70	IC50	20	nM	DIGITOXIGENIN
7.70	IC50	20	nM	CHEMBL2068894
7.70	IC50	20	nM	CHEMBL2068887
7.69	Ki	20.4	nM	CHEMBL5768226
7.66	IC50	22	nM	BUFALIN
7.60	IC50	25	nM	CHEMBL2068888
7.55	IC50	28.2	nM	CHEMBL3350144
7.52	IC50	30	nM	CHEMBL2068896
7.52	IC50	30	nM	CHEMBL2068909
7.50	Ki	31.7	nM	CHEMBL6005633
7.50	Ki	31.5	nM	CHEMBL5814784
7.47	Ki	33.5	nM	CHEMBL5961305
7.41	IC50	38.9	nM	CHEMBL3349024
7.40	IC50	40	nM	CHEMBL126930
7.40	IC50	40	nM	CHEMBL2069036
7.39	Ki	40.7	nM	DIGITOXIN
7.35	IC50	45	nM	CHEMBL2069112
7.30	IC50	50	nM	CHEMBL2069053

PubChem BioAssay actives

210 with measured affinity, of 373 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
3-[(3S,8R,9S,10S,13R,14R,17S)-14-hydroxy-10,13-dimethyl-3-[[(2R,3S,4S,5R,6S)-3,4,5,6-tetrahydroxyoxan-2-yl]methoxy]-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one	49025: Inhibition of [3H]ouabain binding to Na/K ATP-ase in dog heart muscle	ic50	0.0030	uM
3-[(3S,5R,8R,9S,10S,13R,14S,17R)-14-hydroxy-10,13-dimethyl-3-[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one	146845: Inhibition of hog kidney Na+, K+-dependent ATPase	ic50	0.0048	uM
3-[(3S,5R,8R,9S,10S,13R,14S,17R)-3-[(2R,4S,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-14-hydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one	146845: Inhibition of hog kidney Na+, K+-dependent ATPase	ic50	0.0070	uM
3-[(3S,8R,9S,10S,13R,14R,17R)-14-hydroxy-10,13-dimethyl-3-[[(2R,3S,4S,5R,6S)-3,4,5,6-tetrahydroxyoxan-2-yl]methoxy]-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one	49025: Inhibition of [3H]ouabain binding to Na/K ATP-ase in dog heart muscle	ic50	0.0070	uM
3-[(3S,5R,8R,9S,10S,13R,14S,17R)-3,14-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one	56911: Inhibition of [3H]- ouabain binding to digitalis receptor	ic50	0.0080	uM
3-[(3S,5R,8R,9S,10S,13R,14S,17R)-3-[(2R,4S,5S,6R)-5-[(2S,4S,5S,6R)-5-[(2S,4S,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-14-hydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one	56911: Inhibition of [3H]- ouabain binding to digitalis receptor	ic50	0.0080	uM
3-[(3S,5S,8R,9S,10S,13R,14R,17R)-3-[[(2S,3R,4R,6S)-3,4-dihydroxy-6-[[(2S,3R,4R,6S)-3,4,6-trihydroxyoxan-2-yl]methoxy]oxan-2-yl]methoxy]-14-hydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one	49025: Inhibition of [3H]ouabain binding to Na/K ATP-ase in dog heart muscle	ic50	0.0080	uM
3-[(3S,5S,8R,9S,10S,13R,14R,17R)-3-[[(2S,3R,4R,6S)-6-[[(2S,3R,4R,6S)-3,4-dihydroxy-6-[[(2S,3R,4R,6S)-3,4,6-trihydroxyoxan-2-yl]methoxy]oxan-2-yl]methoxy]-3,4-dihydroxyoxan-2-yl]methoxy]-14-hydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one	49025: Inhibition of [3H]ouabain binding to Na/K ATP-ase in dog heart muscle	ic50	0.0080	uM
3-[(3S,5S,8R,9S,10S,13R,14R,17R)-14-hydroxy-10,13-dimethyl-3-[[(2S,3R,4R,6S)-3,4,6-trihydroxyoxan-2-yl]methoxy]-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one	49025: Inhibition of [3H]ouabain binding to Na/K ATP-ase in dog heart muscle	ic50	0.0090	uM
3-[(3S,5R,8R,9S,10S,13R,14S,17R)-14-hydroxy-10,13-dimethyl-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one	146845: Inhibition of hog kidney Na+, K+-dependent ATPase	ic50	0.0105	uM
3-[(3S,5R,8R,9S,10S,13R,14S,17R)-14-hydroxy-10,13-dimethyl-3-[(2R,3S,4S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one	146845: Inhibition of hog kidney Na+, K+-dependent ATPase	ic50	0.0107	uM
(2R,4S,5R)-2-[[(3S,5R,8R,9S,10S,13R,14S,17S)-14-hydroxy-10,13-dimethyl-17-(nitromethyl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl]oxy]-6-methyloxane-3,4,5-triol	56911: Inhibition of [3H]- ouabain binding to digitalis receptor	ic50	0.0120	uM
(3S,5R,8R,9S,10S,13R,14S,17R)-17-[(E,3E)-3-(2-aminoethoxyimino)prop-1-enyl]-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthrene-3,14-diol	146853: 50% displacement of the specific [3H]ouabain binding from the dog kidney Na+/K+ ATPase	ic50	0.0160	uM
3-[(13R)-14-hydroxy-10,13-dimethyl-3-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one	146845: Inhibition of hog kidney Na+, K+-dependent ATPase	ic50	0.0178	uM
(3S,5R,8R,9S,10S,13R,14S,17S)-17-[(E)-3-aminopropoxyiminomethyl]-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthrene-3,14-diol;oxalic acid	146858: In vitro inhibitory concentration against dog kidney Na+/K+ ATPase	ic50	0.0200	uM
5-[(3S,5R,8R,9S,10S,13R,14S,17R)-3,14-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]pyran-2-one	1941870: Inhibition of NA+/K+ ATPase (unknown origin) activity	ic50	0.0220	uM
(3S,5R,8R,9S,10S,13R,14S,17R)-17-[(E,3E)-3-[2-(dimethylamino)ethoxyimino]prop-1-enyl]-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthrene-3,14-diol	146853: 50% displacement of the specific [3H]ouabain binding from the dog kidney Na+/K+ ATPase	ic50	0.0250	uM
(3S,5R,8R,9S,10S,13R,14S,17R)-17-[(E,3E)-3-[2-(dimethylamino)ethoxyimino]prop-1-enyl]-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthrene-3,14-diol;oxalic acid	146858: In vitro inhibitory concentration against dog kidney Na+/K+ ATPase	ic50	0.0300	uM
(3S,5R,8R,9S,10S,13R,14S,17R)-17-[(E,3E)-3-(2-aminoethoxyimino)-2-methylprop-1-enyl]-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthrene-3,14-diol;(E)-but-2-enedioic acid	146858: In vitro inhibitory concentration against dog kidney Na+/K+ ATPase	ic50	0.0300	uM
(2R,4bS,7S,8aR)-2-[(1E,3S)-1-(2-aminoethoxyimino)pentan-3-yl]-7-hydroxy-2,4b-dimethyl-4,4a,5,6,7,8,8a,9,10,10a-decahydro-3H-phenanthren-1-one	146843: Binding affinity towards Na+,K+ -ATPase isolated from dog kidney.	ic50	0.0400	uM
(3S,5R,8R,9S,10S,13R,14S,17S)-17-[(E)-2-(dimethylamino)ethoxyiminomethyl]-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthrene-3,14-diol	146853: 50% displacement of the specific [3H]ouabain binding from the dog kidney Na+/K+ ATPase	ic50	0.0400	uM
(2R,4S,5R)-2-[[(3S,5R,8R,9S,10S,13R,14S,17R)-14-hydroxy-10,13-dimethyl-17-(2-nitroethyl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl]oxy]-6-methyloxane-3,4,5-triol	56911: Inhibition of [3H]- ouabain binding to digitalis receptor	ic50	0.0450	uM
(3S,5R,8R,9S,10S,13R,14S,17S)-17-[(2E)-2-(2-aminoethoxyimino)ethyl]-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthrene-3,14-diol	146843: Binding affinity towards Na+,K+ -ATPase isolated from dog kidney.	ic50	0.0500	uM
(E)-but-2-enedioic acid;(3S,5R,8R,9S,10S,13R,14S,17R)-17-[(E,3E)-3-[2-(dimethylamino)ethoxyimino]-2-methylprop-1-enyl]-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthrene-3,14-diol	146858: In vitro inhibitory concentration against dog kidney Na+/K+ ATPase	ic50	0.0600	uM
6-[[(3S,8R,9S,10S,13R,14R,17S)-14-hydroxy-17-[(1S)-1-hydroxyethyl]-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl]oxy]-2-(hydroxymethyl)oxane-3,4-diol	146854: Compound is evaluated for inhibition of specific binding of [3H]ouabain to membranes from dog heart	ic50	0.0600	uM
3-[(5R,8R,9S,10S,13R,14R,17R)-14-hydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one	49025: Inhibition of [3H]ouabain binding to Na/K ATP-ase in dog heart muscle	ic50	0.0700	uM
(2R,3R,4R,5R,6R)-6-[[(3R)-14-hydroxy-17-(1-hydroxyethyl)-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl]oxymethyl]oxane-2,3,4,5-tetrol	49025: Inhibition of [3H]ouabain binding to Na/K ATP-ase in dog heart muscle	ic50	0.0750	uM
(3S,5R,8R,9S,10S,13R,14S,17R)-17-[(1E,3E)-6-aminohexa-1,3-dienyl]-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthrene-3,14-diol	146858: In vitro inhibitory concentration against dog kidney Na+/K+ ATPase	ic50	0.0800	uM
(3S,5R,8R,9S,10S,13R,14S,17S)-17-[(3Z)-3-(2-aminoethoxyimino)propyl]-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthrene-3,14-diol	146858: In vitro inhibitory concentration against dog kidney Na+/K+ ATPase	ic50	0.0800	uM
3-[(3S,5R,8R,9S,10S,13R,14S,17R)-14-hydroxy-10,13-dimethyl-3-[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one	146845: Inhibition of hog kidney Na+, K+-dependent ATPase	ic50	0.0870	uM
(3S,4R,6R)-6-[[(3S,5R,8R,9S,10S,13R,14S,17S)-14-hydroxy-10,13-dimethyl-17-(nitromethyl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl]oxy]-2-methyloxane-3,4-diol	56911: Inhibition of [3H]- ouabain binding to digitalis receptor	ic50	0.0880	uM
(2R,4S,5R)-2-[[(3S,5R,8R,9S,10S,13R,14S,17S)-17-(aminomethyl)-14-hydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl]oxy]-6-methyloxane-3,4,5-triol;hydrochloride	56911: Inhibition of [3H]- ouabain binding to digitalis receptor	ic50	0.0990	uM
(2R,4bS,7S,8aR)-2-[(1E,3S)-1-[2-(dimethylamino)ethoxyimino]pentan-3-yl]-7-hydroxy-2,4b-dimethyl-4,4a,5,6,7,8,8a,9,10,10a-decahydro-3H-phenanthren-1-one	146843: Binding affinity towards Na+,K+ -ATPase isolated from dog kidney.	ic50	0.1000	uM
(2R,4bS,7S,8aR)-2-[(2S,4E)-4-(2-aminoethoxyimino)butan-2-yl]-7-hydroxy-2,4b-dimethyl-4,4a,5,6,7,8,8a,9,10,10a-decahydro-3H-phenanthren-1-one	146843: Binding affinity towards Na+,K+ -ATPase isolated from dog kidney.	ic50	0.1000	uM
2-[(E)-[(3S,5R,8R,9S,10S,13R,14S,17S)-3,14-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]methylideneamino]guanidine;hydrochloride	146856: Displacement of [3H]ouabain from dog kidney Na+/K+ ATPase	ic50	0.1000	uM
(3S,5R,8R,9S,10S,13R,14S,17S)-17-[(3Z)-3-[2-(dimethylamino)ethoxyimino]propyl]-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthrene-3,14-diol;oxalic acid	146858: In vitro inhibitory concentration against dog kidney Na+/K+ ATPase	ic50	0.1000	uM
(2R,4bS,7S,8aR)-2-[(2S,4E)-4-[2-(dimethylamino)ethoxyimino]butan-2-yl]-7-hydroxy-2,4b-dimethyl-4,4a,5,6,7,8,8a,9,10,10a-decahydro-3H-phenanthren-1-one	146843: Binding affinity towards Na+,K+ -ATPase isolated from dog kidney.	ic50	0.1300	uM
2-(dimethylamino)ethyl (E)-4-[(2R,4bS,7S,8aR)-7-hydroxy-2,4b-dimethyl-1-oxo-4,4a,5,6,7,8,8a,9,10,10a-decahydro-3H-phenanthren-2-yl]hex-2-enoate	146843: Binding affinity towards Na+,K+ -ATPase isolated from dog kidney.	ic50	0.1300	uM
1-[(3R)-14-hydroxy-10,13-dimethyl-3-[[(2R,3R,4R,5R,6R)-3,4,5,6-tetrahydroxyoxan-2-yl]methoxy]-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]ethanone	49025: Inhibition of [3H]ouabain binding to Na/K ATP-ase in dog heart muscle	ic50	0.1500	uM
Digoxin	1970782: Inhibition of NA+/K+ ATPase (unknown origin) activity incubated for 15 mins in presence of ATP by ADP-Glo assay	ic50	0.1600	uM
(2R,4bS,7S,8aS)-2-[(1E,3S)-1-(2-aminoethoxyimino)pentan-3-yl]-7-hydroxy-2,4b-dimethyl-4,4a,5,6,7,8,8a,9,10,10a-decahydro-3H-phenanthren-1-one	146843: Binding affinity towards Na+,K+ -ATPase isolated from dog kidney.	ic50	0.1600	uM
(3S,5R,8R,9S,10S,13R,14S,17S)-17-[(E)-2-aminoethoxyiminomethyl]-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthrene-3,14-diol;(E)-but-2-enedioic acid	146858: In vitro inhibitory concentration against dog kidney Na+/K+ ATPase	ic50	0.1600	uM
2-[(E)-1-[(3S,5R,8R,9S,10S,13R,14S,17S)-3,14-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]ethylideneamino]guanidine	146856: Displacement of [3H]ouabain from dog kidney Na+/K+ ATPase	ic50	0.1995	uM
(3S,5R,8R,9S,10S,13R,14S,17S)-17-[(E)-(4,5-dihydro-1H-imidazol-2-ylhydrazinylidene)methyl]-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthrene-3,14-diol	146856: Displacement of [3H]ouabain from dog kidney Na+/K+ ATPase	ic50	0.1995	uM
(3S,5R,8R,9S,10S,13R,14S,17S)-17-[(2E)-2-(3-aminopropoxyimino)ethyl]-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthrene-3,14-diol	146843: Binding affinity towards Na+,K+ -ATPase isolated from dog kidney.	ic50	0.2000	uM
3-[(1R)-1-[(2R,4bS,7S,8aR)-7-hydroxy-2,4b-dimethyl-1-oxo-4,4a,5,6,7,8,8a,9,10,10a-decahydro-3H-phenanthren-2-yl]propyl]-2H-furan-5-one	146843: Binding affinity towards Na+,K+ -ATPase isolated from dog kidney.	ic50	0.2000	uM
(2R,4bS,7S,8aR)-2-[(1E,3S)-1-(2-aminoethoxyimino)hexan-3-yl]-7-hydroxy-2,4b-dimethyl-4,4a,5,6,7,8,8a,9,10,10a-decahydro-3H-phenanthren-1-one	146843: Binding affinity towards Na+,K+ -ATPase isolated from dog kidney.	ic50	0.2000	uM
(3S,5R,8R,9S,10S,13R,14S,17R)-17-[(E,3E)-3-(3-aminopropoxyimino)-2-methylprop-1-enyl]-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthrene-3,14-diol;oxalic acid	146858: In vitro inhibitory concentration against dog kidney Na+/K+ ATPase	ic50	0.2000	uM
(3S,5R,8R,9S,10S,13R,14S,17S)-17-[(2E)-2-[2-(dimethylamino)ethoxyimino]ethyl]-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthrene-3,14-diol	146843: Binding affinity towards Na+,K+ -ATPase isolated from dog kidney.	ic50	0.2500	uM
2-(dimethylamino)ethyl (E,4R)-4-[(2R,4bS,7S,8aR)-7-hydroxy-2,4b-dimethyl-1-oxo-4,4a,5,6,7,8,8a,9,10,10a-decahydro-3H-phenanthren-2-yl]hex-2-enoate	146843: Binding affinity towards Na+,K+ -ATPase isolated from dog kidney.	ic50	0.2500	uM

CTD chemical–gene interactions

41 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, increases expression	3
sodium arsenite	decreases expression, increases expression	2
entinostat	increases expression, affects cotreatment	2
(+)-JQ1 compound	increases expression	2
Benzo(a)pyrene	increases expression, increases methylation	2
bisphenol F	affects cotreatment, increases expression	1
methylmercuric chloride	decreases expression	1
propionaldehyde	increases expression	1
pirinixic acid	affects binding, decreases expression, increases activity	1
2-methyl-4-isothiazolin-3-one	increases expression	1
trichostatin A	affects cotreatment, affects expression	1
butyraldehyde	increases expression	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression, affects cotreatment	1
pentanal	increases expression	1
Y 27632	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
abrine	increases expression	1
dorsomorphin	increases expression, affects cotreatment	1
Resveratrol	affects cotreatment, decreases expression	1
Decitabine	affects cotreatment, affects expression	1
Sunitinib	decreases expression	1
Aldehydes	increases expression	1
Atrazine	increases expression	1
Dexamethasone	affects cotreatment, increases expression	1
Diethylhexyl Phthalate	decreases expression	1
Drugs, Chinese Herbal	increases expression	1
Indomethacin	affects cotreatment, increases expression	1
Lead	affects expression	1
Lipopolysaccharides	affects response to substance, increases expression, affects cotreatment	1
Naphthoquinones	increases expression	1

ChEMBL screening assays

46 unique, capped per target: 46 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1691887	Binding	Inhibition of human Na+/ K+ ATPase at up to 10 uM	Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1. — Antimicrob Agents Chemother

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.